KIORA PHARMACEUTICALS, INC. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
KIORA PHARMACEUTICALS, INC. (KPRX) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $453.25 thousand as of 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2026-03-25
- 2025-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $453.25K.
- 2024-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $1.70M.
- 2023-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $2.30M.
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $2.56M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs as first filed |
|---|---|---|
| 2025-12-31 | $453.25K 10-K · filed 2026-03-25 | |
| 2024-12-31 | $1.70M 10-K · filed 2026-03-25 | |
| 2023-12-31 | $2.30M 10-K · filed 2025-03-25 | |
| 2022-12-31 | $2.56M 10-K · filed 2024-03-25 | |
| 2021-12-31 | $2.65M 10-K · filed 2023-03-23 | $2.13M 10-K · filed 2022-04-15 |
| 2020-12-31 | $2.40M 10-K/A · filed 2022-07-07 | |
| 2019-12-31 | $986.71K 10-K · filed 2021-03-25 | |
| 2018-12-31 | $904.95K 10-K · filed 2020-03-04 | |
| 2017-12-31 | $919.62K 10-K · filed 2019-03-01 | |
| 2016-12-31 | $1.53M 10-K · filed 2018-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |